Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$74.88 USD

74.88
686,225

+1.34 (1.82%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Globus Medical (GMED) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 10.29% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.

Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise

by Zacks Equity Research

Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.

Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow

by Zacks Equity Research

Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View

by Zacks Equity Research

The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.

Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.

Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

by Zacks Equity Research

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.

Globus Medical (GMED) Global Sales, Innovation Aid Growth

by Zacks Equity Research

In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.

Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

by Zacks Equity Research

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.

Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note

by Zacks Equity Research

QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.

Catalent (CTLT) Expands Its Facility Capabilities in Germany

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Integra's (IART) New Site to Produce Recalled Tissue Products

by Zacks Equity Research

Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.

Should You Keep Chemed (CHE) Stock in Your Portfolio Now?

by Zacks Equity Research

Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.

Here's Why Globus Medical (GMED) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Globus Medical, Inc. (GMED) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GMED vs. SONVY: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMED vs. SONVY: Which Stock Is the Better Value Option?

Here's Why Globus Medical (GMED) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.